Overview

Combination of Rituximab and NK Immunotherapy for B Lymphoma

Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
0
Participant gender:
All
Summary
The aim of this study is the safety and efficacy of Rituximab plus NK immunotherapy to recurrent B lymphoma.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Fuda Cancer Hospital, Guangzhou
Collaborator:
Shenzhen Hank Bioengineering Institute
Treatments:
Rituximab
Criteria
Inclusion Criteria:

- All standard therapies have failed according to NCCN guidelines or the patient refuses
standard therapies after cancer recurrence

- Body tumor 1-6, the maximum tumor length < 5 cm

- KPS ≥ 70, lifespan > 6 months

- Platelet count ≥ 80×109/L,white blood cell count ≥ 3×109/L, neutrophil count ≥
2×109/L, hemoglobin ≥ 80 g/L

Exclusion Criteria:

- Patients with cardiac pacemaker

- Patients with brain metastasis

- Patients with grade 3 hypertension or diabetic complication, severe cardiac and
pulmonary dysfunction